

# SARS-COV-2 DOES NOT STOP PHARMACOLOGISTS

**F. Visioli**

Department of Molecular Medicine, University of Padova, Padova, Italy

**E-mail:** francesco.visioli@unipd.it

**Doi:** 10.36118/pharmadvances.2021.08

The second 2021 issue of *Pharmadvances* is a cornucopia of state-of-the-art papers covering several aspects of modern-day Pharmacology. During this Covid-19 pandemic much attention is being paid to the potential protective actions of vitamin D (1). We still do not know much of its pharmacokinetics (2), but two papers (3, 4) help us better understand its role and its increasing popularity.

It is worth underscoring that the border between the pharmacology of synthetic molecules and those of natural origin is becoming increasingly thinner. It is no coincidence that the Italian Pharmacological Society (SIF) promoted the IUPHAR Mediterranean group of natural products pharmacology (<https://www.imgnpp.org/it>), a trans-national organization that, under the auspices of IUPHAR, is studying and promoting the pharmacology of molecules derived from traditional medicine and from plants. Two notable examples can be found in this issue (5, 6) and we should all pay close attention to the rapid development of this field of research.

Cancer still represents one of the main causes of death and disability and can be in part prevented by a healthy diet and an active lifestyle (7). However, we should put much effort in finding the most appropriate pharmacological treatments, to lessen its burden and improve therapeutic outcomes. *Pharmadvances* publishes two comprehensive reviews on pre-clinical models (8) and on the new frontiers of oncological treatment, i.e. pharmacogenetics (9). Basic pharmacologists and clinicians will find useful information in this June 2021 issue.

From an editorial viewpoint, *Pharmadvances* is evolving rapidly and – together with publisher *Edra* – now offers two important services to help its authorship. One is the “online first” feature, through which accepted

papers are immediately given a DOI and are published online in their raw form. The second one is the possibility for PhD graduates to publish the Introduction of their thesis as single-author review, which is much appreciated by funding bodies. Linked to this, the Italian Pharmacological Society is offering two awards for the best reviews published by newly graduates. Readers will find the details in the Pharmadvances and SIF websites.

In conclusion, Pharmadvances is rapidly positioning itself in the high-level pharmacology literature realm. Thanks to our readership's suggestions the journal will foster research in pharmacology and its manifold manifestations.

Enjoy this issue!

**Prof. Francesco Visioli**  
*Executive Editor*

## REFERENCES

1. Galli F, Reglero G, Bartolini D, Visioli F. Better prepare for the next one. Lifestyle lessons from the COVID-19 pandemic. *PharmaNutrition* 2020;12:100193.
2. Rosen CJ. From gut to blood: the travels and travails of vitamin D supplementation. *Am J Clin Nutr* 2021.
3. Trabace L. Increase in Vitamin D prescriptions in a Southern Italy region over 2011-2015 period. *Pharmadvances* 2021;3(2):467-75. Doi: 10.36118/pharmadvances.2021.02.
4. D'Avolio A. Vitamin D in the COVID-19 prevention and treatment: emerging evidence. *Pharmadvances* 2021 ;3(2):350-6.. Doi: 10.36118/pharmadvances.2021.01.
5. Russo E. Cannabidiol and the central nervous system: translating into clinics. *Pharmadvances* 2021;3(2):369-401. Doi: 10.36118/pharmadvances.2021.04.
6. Dell'Agli M. The pharmacological basis of the curcumin nutraceutical uses: an update. *Pharmadvances* 2021;3(2):421-66.. Doi: 10.36118/pharmadvances.2021.06.
7. The Global Burden of Disease Diet Collaborators. Health effects of dietary risks in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2019;393(10184):1958-72.
8. Lisi L. Preclinical models in oncological pharmacology: limits and advantages. *Pharmadvances* 2021;3(2):402-20.. Doi: 10.36118/pharmadvances.2021.05.
9. Toffoli G. Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers. *Pharmadvances* 2021;3(2):357-68.. Doi: 10.36118/pharmadvances.2021.03.